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To assess the ability of [
18F]ﬂuorodeoxyglucose positron emission tomography for the early prediction of response in patients
with relapsed metastatic germ cell tumours undergoing salvage high-dose chemotherapy. The role of positron emission
tomography was compared with established means of tumour response assessment such as CT scans/MRI and serum tumour
marker changes. In addition, positron emission tomography was compared with a current prognostic score which differentiates
three prognostic groups with failure-free survival rates ranging from 5–50%. [
18F]ﬂuorodeoxyglucose uptake of metastases
from germ cell tumours as well as CT scans and serum tumour marker were acquired after 2–3 cycles of induction
chemotherapy but before the start of high-dose chemotherapy and CT scans/serum tumour marker were compared with the
baseline examinations in 23 patients with relapsed germ cell tumours. To evaluate the validity of early response prediction by
positron emission tomography, radiological monitoring and serum tumour marker decline, histopathologic response after
resection of residual masses and/or the clinical course over 6 months after the end of treatment (relapse vs freedom of
progression) were used. Overall, 10 patients (43%) achieved a marker-negative partial remission, three (13%) a marker-
positive partial remission, ﬁve (22%) a disease stabilization and ﬁve (22%) progressed during treatment. Nine patients (39%)
remained progression-free over 6 months following treatment, whereas 14 (61%) progressed. The outcome of high-dose
chemotherapy was correctly predicted by positron emission tomography/CT scan/serum tumour marker in 91/59/48%. Eight
patients with a favourably predicted outcome by CT scans plus serum tumour marker but a positive positron emission
tomography prior to high-dose chemotherapy, failed treatment. This results in the following sensitivities/speciﬁcities for the
prediction of failure of high-dose chemotherapy: positron emission tomography 100/78%; radiological monitoring 43/78%;
serum tumour marker 15/100%. The positive and negative predictive values of positron emission tomography were 88 and
100%, respectively. As compared with the prognostic score, positron emission tomography was correctly positive in all
patients of the three risk groups who failed treatment. In addition, a negative positron emission tomography correctly
predicted a favourable outcome in the good and intermediate group. [
18F]ﬂuorodeoxyglucose positron emission tomography
imaging can be used to assess response to chemotherapy in patients with relapsed germ cell tumours early in the course of
treatment and may help to identify patients most likely to achieve a favourable response to subsequent high-dose
chemotherapy. In patients with response to induction chemotherapy according to CT scans or serum tumour marker
evaluation, positron emission tomography seems to add information to detect patients with an overall unfavourable outcome.
It may also be a valuable addition to the prognostic model particularly in the good and intermediate group for further
selection of patients who will proﬁt from high-dose chemotherapy.
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The development of cisplatin-based combination chemotherapy has
dramatically improved the prognosis of patients with metastatic
germ cell cancer, resulting in a long-term cure rate of 70–80%
(Einhorn, 1990; Hartmann et al, 1999). However, patients relapsing
after cisplatin-based ﬁrst-line chemotherapy exhibit unsatisfactory
survival rates of only 20–30% following standard-dose cisplatin-
based salvage chemotherapy (Rick et al, 1999). In these patients,
high-dose chemotherapy (HD-CTX) with autologous hematopoie-
tic stem cell support has been widely investigated in order to
improve their outcome. Studies have suggested a potential survival
improvement of 10–20% using HD-CTX, but this survival increase
has not yet been conﬁrmed by a randomized trial (Broun et al,
1995; Motzer et al, 1996; Beyer et al, 1999; Rick et al, 2001).
However, HD-CTX is associated with more frequent side effects
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chemotherapy. Thus, it is of great interest, whether one can iden-
tify early those patients who will beneﬁt from HD-CTX and those
who will not (Anthoney and Kaye, 1999; Decartis et al, 2000).
Clinical prognostic factors for salvage chemotherapy have been
proposed in order to identify those patients with a very poor prog-
nosis despite the use of salvage HD-CTX and distinguish them
from patients with an intermediate or good chance for success of
HD-CTX. These unfavourable prognostic factors include high ß-
HCG levels, disease refractory to platin-based chemotherapy,
primary mediastinal tumour and disease progression prior to
HD-CTX (Beyer et al, 1996). Based on these factors, patients can
be classiﬁed prior to the start of salvage therapy into three risk
groups, good, intermediate and poor, with a likelihood of 2 year
failure-free survival of 51, 27 and 5%, respectively.
For assessing the tumour response during treatment, both the
timely decline of tumour markers and the documentation of
morphologic changes in tumour size by radiological methods such
as CT scan or MRI have been used up to date. However, the
decline of serum tumour markers depends on certain metabolic
pathways, which may be of different capacity in individual patients
(deWit et al, 1997; Motzer et al, 1997; Zon et al, 1998; Christensen
et al, 1999). Prediction of response during chemotherapy by
tumour marker decline alone may be misleading. Radiological
imaging for the assessment of tumour response may also be of
limited value due to the delay between the start of treatment and
tumour shrinkage and due to the inability of radiological imaging
techniques to differentiate vital carcinoma from necrosis or scar
tissue in case of residual lesions. Thus, additional means for the
monitoring of treatment response may be helpful to identify
non-responding patients and to avoid ineffective and toxic treat-
ment.
Positron emission tomography (PET) imaging using 2-
[
18F]ﬂuoro-2-deoxy-D-glucose (F-18 FDG) is a new diagnostic
technique which allows visualization and quantiﬁcation of regional
glucose metabolism within the body (Strauss and Conti, 1991;
Hawkins et al, 1992). Since cancer cells are characterized by a
higher glucolytic rate than normal tissue cells, PET exploits this
difference by assessing the rate and quantity of F-18 FDG uptake
by the tumour. Studies have investigated the role of PET for the
evaluation of residual masses in patients with germ cell tumours
(GCT) after chemotherapy demonstrating the additional value of
PET imaging for the detection of viable carcinoma in residual
masses of both patients with seminomatous and non-seminoma-
tous germ cell cancer (Stephens et al, 1996; Cremerius et al,
1998; Ganjoo et al, 1999; De Santis et al, 2001; Kollmannsberger
et al, 2002). However, no study has so far reported the ability of
PET to predict response during standard-dose or HD-CTX in
patients with germ cell cancer.
Thus, the primary aim of the present prospective study was to
evaluate the general ability of PET to predict response to salvage
chemotherapy in patients with relapsed metastatic germ cell cancer.
In-vivo chemotherapy sensitivity testing by PET was correlated
with the overall outcome of the patient following subsequent
HD-CTX. In addition, PET was compared with the above
described prognostic score for high-dose salvage chemotherapy
(Beyer et al, 1996) as well as to the tumour marker decline and
assessment radiological imaging, which are the currently established
methods for assessment of response to chemotherapy
MATERIALS AND METHODS
Patients and treatment
Patients with relapsed disease after cisplatin-based ﬁrst-line
chemotherapy participating in the prospective German multicenter
HD-CTX trial between September 1995 and October 1999 were
eligible for inclusion into the PET protocol (Mead for the Interna-
tional Germ Cell Cancer Collaborative Group, 1997; Rick et al,
2001). All patients were treated at Tuebingen University Medical
Center. Eligibility criteria for high-dose salvage chemotherapy
consisted of the following: relapsed GCT of any primary tumour
site after ﬁrst-line chemotherapy treatment, Karnofsky performance
status 450%, normal kidney function, absence of severe heart or
liver disease and written informed consent. Patients were treated
with three cycles of standard-dose TIP-chemotherapy followed by
one cycle of TEC-HD-CTX. Standard-dose TIP-chemotherapy
consisted of paclitaxel 175 mg m
72 given on day 1 and ifosfamide
1200 mg m
72 and cisplatin 20 mg m
72 both administered daily
on days 2 through 6 of a 22-days cycle. The TEC-high-dose regi-
men contained thiotepa 150 mg m
72, etoposide 600 mg m
72
and carboplatin 500 mg m
72, all drugs given daily over 3 days.
All patients received autologous peripheral blood stem cell support
and granulocyte-colony stimulating factor after HD-CTX according
to treatment protocol and institutional practice. The results of this
trial have been previously published (Rick et al, 2001).
All patients were treated at Tuebingen University Medical
Center. Both studies, the HD-CTX trial as well as the present
PET study were approved by the Ethical Committee of the Univer-
sity of Tuebingen. All patients were required to provide informed
consent before study entry.
Tumour response evaluation
All patients underwent extensive staging procedures including CT
scan or MRI of the chest, abdomen, and brain, determination of
serum tumour marker (TUM) levels (ß-HCG, AFP, LDH) as well
as a baseline PET imaging prior to the start of chemotherapy.
All staging procedures were performed within 5 days in order to
allow comparisons. Determination of TUM levels were repeated
prior to each of the subsequent chemotherapy cycles and CT scans
and/or MRI of the tumour lesions after every second cycle. Induc-
tion chemotherapy included the three standard-dose chemotherapy
cycles. Within 8 days prior to the planned high-dose TEC therapy,
PET imaging, CT scan and/or MRI of the tumour lesions as well as
a determination of TUM levels were repeated (Figure 1). After
completion of salvage chemotherapy, all residual masses in patients
with non-seminomatous germ cell cancer were resected, if techni-
cally possible. All patients underwent follow-up examinations
including evaluation of tumour marker levels and CT scans in 3-
monthly intervals.
All CT/MRI scans were reviewed by an independent, board-
certiﬁed radiologist who was not aware of the PET ﬁndings.
Response was classiﬁed according to modiﬁed WHO criteria
(deWit et al, 1998).
A partial or complete remission on CT scan as well as normal-
ized or declining TUM (490% decline compared with baseline
value) during chemotherapy were classiﬁed as a favourable
response predicting a successful outcome. Stable disease or disease
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High-dose chemotherapy for relapsed disease (n=23):
TIP TIP TIP HD-TEC sec. surgery
TUM
CT/MRI
TUM
CT/MRI
PET
TUM TUM TUM
CT/MRI
PET
Abbreviations: sec.=secondary; Tum=tumor marker levels; TIP=Paclitaxel,
ifosamide, cisplatin combination chemotherapy; HD-TEC=high-dose
chemotherapy with thiotepa, etoposide, carboplatin; CT=computer
tomography; MRI=magnetic resonance imaging; PET=positron emission
tomography.
Figure 1 Schedule of CT/MRI and PET examinations for response
assessment during chemotherapy according to the protocol.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 506–511progression on CT scan or a tumour marker decrease 590% or
increasing markers prior to HD-CTX were considered as an
unfavourable response and thus predictive for treatment failure.
PET imaging
A dedicated PET scanner (ADVANCE, General Electrics Medical
Systems, Milwaukee, WI, USA) was used, providing an axial ﬁeld
of view (FOV) of 15.3 cm. Emission data were corrected for
random events, attenuation and scattering. Per FOV 35 slices
(4.25 mm) were reconstructed iteratively or by ﬁltered back projec-
tion with a 1286128 pixel matrix (4.364.3 mm pixel size)
resulting in a ﬁnal resolution of about 8 mm (full width at half
maximum).
All patients fasted for at least 12 h before PET imaging. Blood
glucose levels were checked for each patient before the intravenous
administration of 250–500 MBq of F-18 FDG. In all patients, 1–3
FOVs were imaged depending on the lesions found on CT scan.
Forty-ﬁve to 60 min after the F-18 FDG injection, static PET-scans
were recorded for 5–15 min per FOV (depending on reconstruc-
tion algorithm, injected radioactivity and patient weight).
Transmission scanning (10–20 min resp. 500000 kcts per FOV;
sinogram windowing) was performed before F-18 FDG-injection
or after emission scanning. After tracer injection, patients received
at least 1 l of normal saline and 20 mg furosemide in order to
minimize image artefacts from residual radioactivity in the urinary
tract.
PET image analysis
Each PET was reviewed by an experienced nuclear medicine physi-
cian, who was blinded to the TUM course as well as to the
interpretation of the results of CT scan and/or MRI. Standardized
uptake values (SUV), a quantitative measure of tumour uptake of
the tracer, adjusted for injected dose and body weight, were calcu-
lated, if an increased uptake was observed in the tumour area
(Leskinen et al, 1991; Strauss and Conti, 1991). Patients with a
SUV of 52 were considered positive (Kollmannsberger et al,
2002).
PET ﬁndings after induction chemotherapy were also correlated
to the histological ﬁndings of the residual mass in those patients
who received a secondary resection after completion of chemother-
apy treatment. If no resection of residual tumour masses was
performed, the clinical course of the patient was used. If no radi-
ological tumour progression or increase of tumour markers were
observed within 6 months after the end of therapy, the residual
tumour was considered avital. The 6 month interval was chosen
since clinically a disease-free interval of at least 6 months appears
to justify the physical and ﬁnancial expenses of HD-CTX with stem
cell support.
RESULTS
Twenty-three patients receiving HD-CTX for relapsed germ cell
cancer were evaluated with F-18 FDG-PET imaging before the start
of treatment as well as during the course of treatment. Character-
istics of the patients are listed in Table 1. Baseline PET prior to the
start of chemotherapy was positive in all lesions evaluated in this
study.
In 14 patients the clinical course over 6 months was monitored
while in the other nine patients the histology following secondary
resection of residual masses was available. Overall, nine patients
(39%) remained progression-free for at least 6 months following
HD-CTX, whereas 14 (61%) patients relapsed within this time
period. Median follow-up was 27 months (10–55 months) for
all patients and only three patients relapsed beyond the follow-
up period of 6 months after the PET examination (8, 16 and 18
months after the PET examination).
Outcome prediction by PET
Overall, the clinical course of disease after HD-CTX was correctly
predicted by PET imaging during chemotherapy in 21 of 23
patients (91%). A negative PET (SUV 52) after the initial part
of treatment was found in seven patients (30%) and none of these
patients failed after the completion of the full treatment regimen.
In 16 patients (70%) PET was still positive prior to the actual
HD-CTX cycles. Fourteen of these patients either relapsed within
6 months following HD-CTX or the histology of the resected resi-
dual tumour mass after HD-CTX still revealed the presence of vital
carcinoma. Two patients with a positive PET (SUV 52) prior to
the HD-CTX still had a favourable outcome. In the ﬁrst patient
a SUV of 5.4 (pulmonary metastasis) and in the second patient a
SUV of 7.5 (mediastinal mass) suggested the presence of gross vital
carcinoma and thus poor response to induction chemotherapy.
However, histology of the resected masses after the completion
of therapy only showed necrosis in both patients. Thus, sensitivity
and speciﬁcity of PET for the prediction of the overall failure of
salvage chemotherapy are 100 and 78%, respectively. The positive
predictive value of PET for treatment failure was 88%, whereas
the negative predictive value of PET was 100% (Table 2).
Comparison of PET to CT scan/MRI for the prediction of
therapy response
Comparisons of PET to CT scan/MRI performed at the same time
point during chemotherapy were available for 22 patients. In one
patient no corresponding CT scan was performed. Overall, CT
scans/MRI correctly predicted the outcome after therapy in 13
(59%) patients. CT scans/MRI correctly indicated a non-responding
tumour in six patients, four of whom showed stable disease and two
progressive tumour lesions during chemotherapy. All of these six
patients also had a positive PET during chemotherapy. Seven
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Table 1 Patient characteristics (n=23)
Median age 31 (21–60)
Histology
Seminoma 2 (9%)
Non-seminoma 21 (91%)
Primary tumour localization
Gonadal 21 (21%)
Extragonadal 2 (9%)
Location of metastases
Abdominal mass 17 (74%)
Lungs 12 (52%)
Mediastinum 4 (17%)
Liver 5 (22%)
Bone 5 (22%)
Other 4 (17%)
Patients with elevated serum tumour marker
b-HCG 15 (65%)
AFP 8 (35%)
LDH 5 (22%)
None 2 (9%)
Response to therapy
PR marker negative 10 (43%)
PR marker positive 3 (13%)
Stable disease 5 (22)
Progression 5 (22%)
Secondary resection (n=9)
Vital carcimoma 3 (33%)
Mature teratoma 1 (11%)
Necrosis 5 (56%)
Course of disease after the end of therapy
No disease progession (for at least 6 months) 9 (39%)
Disease progression (within 6 months) 14 (61%)
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of their metastases on CT scans/MRI after induction therapy. Only
ﬁve of these patients were PET negative, whereas in two patients the
PET still showed increased SUV-values prior to high-dose
chemotherapy. CT scans/MRI during therapy were not able to
correctly predict the outcome in nine patients. Eight of these
patients showed a remission of metastases on CT scan/MRI but still
had an unfavourable response. One patient remained disease-free
after treatment despite the CT scans showing a stable disease prior
to the HD-CTX. All of these nine patients had PET results correctly
predicting the overall response, eight still being positive and one
already being negative. Thus, the sensitivity and speciﬁcity of CT
scans/MRI (SD or PD predicting an unfavourable outcome) were
43 and 88% respectively. The positive and negative predictive values
of CT scans/MRI were 86 and 47%, respectively (Table 2).
Comparison of PET to TUM decline for the prediction of
therapy outcome
The comparison of PET to TUM decline during therapy included
21 patients since two patients never had had elevated markers.
The response to HD-CTX by tumour marker decline was correctly
predicted in 10 patients (48%). In two patients tumour markers
remained elevated or even increased during therapy and both
patients failed treatment. These two patients also showed a positive
PET scan prior to HD-CTX. Tumour marker decline correctly
predicted a favourable outcome in eight patients, ﬁve of whom
had already normalized and three declining markers during
chemotherapy. PET was also already normalized in seven of these
eight patients, but in one patient PET was still positive prior to
HD-CTX. The decline (nine patients) or normalization (two
patients) of tumour markers indicated a favourable outcome in
11 further patients, but all of these failed treatment. In contrast,
PET correctly predicted the course of disease in these 11 patients.
There were no patients with a false positive elevation of tumour
markers. The sensitivity and speciﬁcity of tumour marker elevation
indicating treatment failure were 15 and 100%, respectively. The
positive predictive value was 100% and the negative predictive
value 42% (Table 2).
Comparison of PET to the combined assessment by CT
scans/MRI and serum marker decline
For the comparison of PET to the combination of CT scan/MRI plus
TUM decline data from 20 patients were available. Two patients
never had elevated tumour markers and in one patient no corre-
sponding CT scan was performed at the time of PET imaging. Of
20 patients, response to treatment was correctly predicted by the
combination of CT scan/MRI plus tumour marker decline in 12
patients (60%). Five patients showed a stable disease/tumour
progression on CT scans/MRI as well as a persisting elevation/
increase of tumour markers. All of these ﬁve patients relapsed after
HD-CTX. PET imaging performed during chemotherapy was posi-
tive in these ﬁve patients. CT scans/MRI ﬁndings as well as tumour
markers were improved following induction chemotherapy in seven
patients correctly indicating a favourable outcome. PET was also
predictive in six of these seven patients whereas in one patient the
PET prior to HD-CTX was still markedly positive. However, in eight
patients the combination of CT scan/MRI plus tumour marker
decline suggested a favourable response to chemotherapy, while the
positive PET scan during chemotherapy in all of these eight patients
correctly predicted their unfavourable outcome (Table 3).
Comparison of F-18 FDG PET with the prognostic score by
Beyer et al (1996)
Based on the prognostic factors described by Beyer et al (1996) nine
patients (39%) belonged to the good risk group, another nine
patients (39%) to the intermediate group and the remaining ﬁve
patients (22%) to the poor risk group. Three patients in the good risk
group, six patients in the intermediate group and all patients in the
poor risk group relapsed after salvage HD-CTX. PET performed
during salvage chemotherapy was positive in all of these patients
correctly predicting their unfavourable outcome. PET was correctly
negative in ﬁve of six patients and in two of three patients in the
good and intermediate group, respectively, who remained relapse-
free after treatment. In two patients, one in the good and one in
intermediate risk group, PET showed an increased F-18 FDG uptake
prior to HD-CTX, suggesting an unfavourable outcome, but both
patients remained relapse-free following treatment. There were no
false negative PET results in any of the three groups (Table 4).
DISCUSSION
Over the last decade, HD-CTX with autologous stem cell support
has been widely investigated as salvage therapy for patients with
refractory or relapsed germ cell cancer (Motzer et al, 1996; Bhatia
et al, 1998; Rick et al, 2001). Since not all patients will beneﬁt to
the same amount from this treatment, prognostic scores have been
developed in order to identify those patients who are most likely to
respond (Beyer et al, 1996) and thus, in whom the physical and
ﬁnancial costs of HD-CTX can be justiﬁed (Anthoney and Kaye,
1999; Decartis et al, 2000). It was the aim of the present study
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Table 2 Comparison of the sensitivity, speciﬁcity and negative and posi-
tive predictive values of PET, CT scans/MRI and serum tumour markers
PET CT scans/MRI Tumour markers
Parameter (n=23) (n=22)
a (n=21)
b
Sensitivity 100% 43% 15%
Speciﬁcity 78% 88% 100%
Negative predictive value 100% 47% 42%
Positive predictive value 88% 86% 100%
aIn one patient no corresponding CT scan was performed.
bTwo patients never had
elevated markers.
Table 3 Comparison of PET to CT scan plus serum tumour markers
CT/MRT+ CT/MRT+ CT/MRT+
tumour marker tumour marker tumour marker
Correct positive Correct negative Not correct Total
a
PET correct positive 5 0 8 13
PET correct negative 0 6 0 6
PET false positive 0 1 0 1
PET false negative 0 0 0 0
Total 5 7 8 20
a
aTwo patients without elevated tumour markers at diagnosis and one patient without corresponding CT scan excluded (PET false
positive).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 506–511to determine whether metabolic monitoring using PET early in the
course of salvage chemotherapy can be used to predict the overall
response to treatment and indicate the outcome in patients with
relapsed germ cell cancer. Moreover, the value of PET imaging
was investigated comparing it to an established prognostic model
as well as to conventional means of response assessment such as
CT scans/MRI and the changes of TUM levels.
Studies in different tumour types have demonstrated the ability
of PET to clinically document tumour response to chemotherapy
as well as its diagnostic value in the staging of cancer (Huovinen
et al, 1993; Findlay et al, 1996; Flamen et al, 1999; Kollmannsberger
et al, 2002). Wahl et al (1993) were among the ﬁrst who reported
that PET may have a substantial role as an early non-invasive
method for the assessment of the efﬁcacy of treatment. Two
recently published reports suggest that F-18 FDG-PET may be
valuable for the prediction of response to neoadjuvant chemother-
apy in patients with advanced breast cancer. Schelling et al (2000)
demonstrated that in breast cancer patients F-18 FDG-PET can
differentiate responders from non-responders already after the ﬁrst
cycle of neoadjuvant chemotherapy with a high rate of accuracy.
Similar results were reported by Smith et al (2000). In patients with
pancreatic cancer, PET has been reported to be superior to
response assessment by conventional radiographical methods and
may subsequently predict survival (Maisey et al, 2000).
In the current study in patients with relapsed germ cell cancer,
PET performed after the initial cycles of salvage induction
chemotherapy was able to correctly predict the outcome of HD-
CTX in 91% of patients. A negative PET prior to HD-CTX appears
to be a strong predictor for a favourable outcome, since none of
these patients failed treatment. In contrast, a PET still remaining
positive after the ﬁrst chemotherapy cycles was highly predictive
for an overall unfavourable outcome despite the use of subsequent
HD-CTX. Only in two patients with an overall favourable response,
PET results were still positive prior to HD-CTX. Histology revealed
necrosis combined with inﬂammation in both cases. In these two
cases, either PET may have been correctly positive and HD-CTX
may have eradicated the vital tumour or PET may have been false
positive due to an inﬂammatory process. F-18 FDG is not a
tumour-speciﬁc agent and it may also accumulate in tissue macro-
phages. This phenomenon is a major source of false-positive PET
examinations in cancer patients (Strauss, 1996; Flamen et al,
1999). In order to reduce the rate of false positive ﬁndings it is
necessary to correlate the PET results with data from other meth-
ods for response assessment such as CT scans and the decline of
previously elevated tumour markers. Considering separately the
sensitivities and speciﬁcities of F-18 FDG-PET, and radiological
response, our results indicate that no method by itself is sufﬁciently
accurate to predict the overall treatment result.
To our knowledge, this is the ﬁrst study which compares F-18
FDG-PET to the prognostic model based on clinical factors. This
study also compares 18F-FDG PET results with established criteria
for response assessment in patients with metastatic germ cell
cancer. PET may be a valuable addition to the established prognos-
tic model developed by Beyer et al (1996) and may be able to
further select patients particularly in the good and intermediate
risk group who will or will not proﬁt from salvage HD-CTX. A
positive PET prior to HD-CTX appears to be highly predictive
for an unfavourable outcome despite ‘good risk’ prognostic
features. In contrast, a negative PET prior to HD-CTX seems to
reliably predict an favourable outcome even if the patient exhibits
unfavourable prognostic characteristics.
Since this study was performed prospectively with blinded read-
ing of CT scans/MRI, and PET, none of the diagnostic physicians
was aware of the results of the corresponding tests. Thus, differences
in sensitivity and speciﬁcity can be directly compared based on the
results obtained in this study. As compared with CT scans/MRI and
tumour markers, PET seems to offer additional information regard-
ing treatment outcome in a large number of patients. Persisting or
even increasing tumour markers as well as progressive disease on
CT scan/MRI during chemotherapy are strong predictors for an
unfavourable outcome of treatment. In these patients PET was not
able to add additional information regarding response. However,
the potential beneﬁt of PET was observed in patients with stable
disease or remissions on CT scan/MRI and/or declining or normal-
ized tumour markers. These patients form the largest subgroup. In
these patients an elevated F-18 FDG uptake correctly predicted the
unfavourable outcome of eight patients in whom CT scans/MRI
and the tumour marker course suggested a favourable response to
therapy. One of the most important factors for the success of
HD-CTX in relapsed patients is responsiveness of disease to
previous platin-based therapy. Using PET as an early method of
response assessment, this non-invasive technique seems to offer
the chance for in-vivo chemosensitivity testing during treatment.
However, the limitations of the present study have to be consid-
ered. The number of patients included was small which might
cause misleading results. Larger studies are necessary to conﬁrm
these results. A second limitation of the present study could be
the methodology used to conﬁrm the prediction of PET. Whereas
it would have been ideal to have a histological diagnosis of all
tumours at the time of response prediction, this was certainly
not feasible during the course of chemotherapy. The prediction
of response is largely based on the follow-up of the patients over
6 months after HD-CTX. Since relapse or progression of germ cell
cancer, once present, usually occurs rapidly after the end of treat-
ment, the data obtained in this study may still be valid. Most of the
relapses in our study occurred within 6 months after treatment.
However, three patients relapsed beyond the 6 months follow-up
period indicating that PET similar to other methods of response
assessment may be unable to predict for late relapses.
Our study has intentionally focused on a speciﬁc population of
germ cell cancer patients who are at a high risk for incomplete
response and relapse. This study population served as a model for
the evaluation of the ability of PET to predict response to treatment
already during the course of therapy. The high rate of non-respond-
ing/relapsing patients allows the evaluation of PET’s predictive value
as a ‘proof of principle’. PET performed in conjunction with clinical
prognostic factors as well as conventional staging methods appears to
offer additional information for response prediction during
chemotherapy. Whether patients with a negative PET after three
cycles of conventional-dose salvage chemotherapy beneﬁt from
subsequent HD-CTX or may have a similar favourable outcome with
one additional conventional-dose chemotherapy cycle is presently
unclear and remains the objective of future studies. Nevertheless, at
this point in time it is not justiﬁed to derive treatment decisions from
PET results alone. The predictive value of PET should now also be
examined in patients with earlier stages of metastatic disease, where
treatment intensiﬁcation may still be a therapeutic option.
Since PET imaging performed early in the course of treatment
may provide independent prognostic information, a multivariate
analysis needs to investigate its impact in relation to other clinical
and biological prognostic factors. Moreover, the early identiﬁcation
of non-responding patients by PET may help to avoid ineffective
HD-CTX and thus, reduce toxicity and treatment costs in these
patients.
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Table 4 Comparison of PET to the prognostic model for the prediction
of response to salvage high-dose chemotherapy (n=23) (Beyer et al, 1996)
PET TP PET TN PET FP PET FN Total
Good risk 3 5 1 0 9
Intermediate risk 6 2 1 0 9
Poor risk 5 0 0 0 5
Total 14 7 2 0 23
TP=true positve, TN=true negative; FP=false positive; FN=false negative.
PET for prediction of response to HD-CTX in germ cell cancer
C Bokemeyer et al
510
British Journal of Cancer (2002) 86(4), 506–511 ã 2002 Cancer Research UKREFERENCES
Anthoney DA, Kaye S (1999) Treatment for poor prognosis metastatic germ-
cell tumours: Much heat but, yet, little light. Ann Oncol 10: 255–258
Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL,
Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W
(1996) High-dose chemotherapy as salvage treatment in germ cell tumors:
A multivariate analysis of prognostic variables. J Clin Oncol 14: 2638–2645
Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (1999) High-dose versus
conventional-dose ﬁrst-salvage treatment in nonseminoma: a matched-
pair analysis. Proc Am Soc Clin Oncol 18: 326a (abstract 1255)
Bhatia S, Cornetta K, Broun ER, Nichols CR, Abonour R, Einhorn LH (1998)
High-dose chemotherapy with peripheral stem cell or autologous bone
marrow transplant as initial salvage chemotherapy for testicular cancer.
Proc Am Soc Clin Oncol 17: 321a
Broun ER, Nichols CR, Mandanas R, Salzman D, Turns M, Hromas R,
Cornetta K, Einhorn LH (1995) Dose escalation study of high-dose carbo-
platin and etoposide with autologous bone marrow support in patients
with recurrent and refractory germ cell tumors. Bone Marrow Transplant
16: 353–358
Christensen TB, Engbaek F, Marqversen J, Nielsen SI, Kamby C, von der
Masse H (1999) 125I-labelled human chorionic gonadotrophin (hCG) as
an elimination marker in the evaluation of hCG decline during chemother-
apy in patients with testicular cancer. Br J Cancer 80: 1577–1581
Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, Jakse
G, Buell U (1998) FDG PET for detection and therapy control of metastatic
germ cell tumor. J Nucl Med 39: 815–822
De Santis M, Bokemeyer C, Becherer A, Stoiber F, Occhsle K, Kletter K,
Dohmen BM, Dittrich C, Pont J (2001) Predictive impact of 2-18ﬂuoro-
2-deoxy-D-glucose positron emission tomography for residual postche-
motherapy masses in patients with bulky seminoma. J Clin Oncol 19:
3740–3744
Decartis MP, Wilkinson P, Welch RS, Metzner M, Morgenstern GR, Dougall
M (2000) High-dose chemotherapy and autologous haematopoietic
support in poor risk non-seminomatous germ-cell tumors: an effective
ﬁrst-line therapy with minimal toxicity. Ann Oncol 11: 427–434
deWit R, Stoter G, Sleijfer DT, Neijt JP, ten-Bokkel HW, de Prijck L, Collette
L, Sylvester R (1998) Four cycles of BEP vs four cycles of VIP in patients
with intermediate-prognosis metastatic testicular non-seminoma: a rando-
mized study of the EORTC Genitourinary Tract Cancer Cooperative
Group. European Organization for Research and Treatment of Cancer.
Br J Cancer 78: 828–832
deWit R, Sylvester R, Tsitsa C, de Mulder P, Sleyfer DT, ten-Bokkel HW,
Kaye SB, van OA, Boven E, Vermeylen K, Stoter G (1997) Tumour marker
concentration at the start of chemotherapy is a stronger predictor of treat-
ment failure than marker half-life: a study in patients with disseminated
non-seminomatous testicular cancer. Br J Cancer 75: 432–435
Einhorn LH (1990) Treatment of testicular cancer: A new and improved
model. J Clin Oncol 8: 1777–1781
Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B,
Husband J, Flower M, Ott R (1996) Noninvasive monitoring of tumor
metabolism using ﬂuorodeoxyglucose and positron emission tomography
in colorectal cancer liver metastases: correlation with tumor response to
ﬂuorouracil. J Clin Oncol 14: 700–708
Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N,
Penninckx F, Van Hoe L, Mortelmans L (1999) Additional value of whole-
body positron emission tomography with ﬂuorine-18-2-ﬂuoro-2-deoxy-
D-glucose in recurrent colorectal cancer. J Clin Oncol 17: 894–901
Ganjoo KN, Chan RJ, Sharma M, Einhorn LH (1999) Positron emission
tomography scans in the evaluation of postchemotherapy residual masses
in patients with seminoma. J Clin Oncol 17: 3457–3460
Hartmann JT, Kanz L, Bokemeyer C (1999) Diagnosis and treatment of
patients with testicular germ cell cancer. Drugs 58: 257–281
Hawkins RA, Choi Y, Huang SC, Messa C, Hoh CK, Phelps ME (1992) Quan-
titating tumor glucose metabolism with FDG and PET (editorial;
comment). J Nucl Med 33: 339–344
Huovinen R, Leskinen KS, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M
(1993) Carbon-11-methionine and PET in evaluation of treatment
response of breast cancer. Br J Cancer 67: 787–791
Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg ABR, Claussen C,
Kanz L, Bokemeyer C (2002) Prospective comparison of [
18F]-FDG PET
with conventional assessment by CT scans and serum tumor markers for
the evaluation of residual masses in non-seminomatous germ cell cancer
patients. Cancer in press
Leskinen KS, Nagren K, Lehikoinen P, Ruotsalainen U, Joensuu H (1991)
Uptake of 11C-methionine in breast cancer studied by PET. An association
with the size of S-phase fraction. Br J Cancer 64: 1121–1124
Maisey NR, Webb A, Flux GD, Padhani A, Cunningham D, Ott R, Norman A
(2000) FDG-PET in the prediction of survival of patients with cancer of the
pancreas: a pilot study. Br J Cancer 83: 287–292
Mead G for the International Germ Cell Cancer Collaborative Group (1997)
International Germ Cell Consensus Classiﬁcation: a prognostic factor-
based staging system for metastatic germ cell cancers. International Germ
Cell Cancer Collaborative Group. J Clin Oncol 15: 594–603
Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V (1997) High-
dose carboplatin, etoposide, and cyclophosphamide with autologous bone
marrow transplantation in ﬁrst-line therapy for patients with poor-risk
germ cell tumors. J Clin Oncol 15: 2546–2552
Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V
(1996) High-dose carboplatin, etoposide, and cyclophosphamide for
patients with refractory germ cell tumors: treatment results and prognostic
factors for survival and toxicity. J Clin Oncol 14: 1098–1105
Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neur-
either S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs
H-G, Gerl A, Berdel W, Kanz L, Siegert W (2001) Salvage treatment with
paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide,
and thiotepa followed by autologous stell cell rescue in patients with
relapsed or refractory germ cell cancer. J Clin Oncol 19: 81–88
Rick O, Siegert W, Beyer J (1999) High-dose salvage chemotherapy. Germ cell
tumor treatment results in Germany. Int J Cancer 83: 839–840
Schelling M, Avril N, Na ¨hrig J, Kuhn W, Ro ¨mer W, Sattler D, Werner M,
Dose J, Ja ¨nicke F, Graeff H, Schwaiger M (2000) Positron emission tomo-
graphy using [
18F]-ﬂuorodeoxyglucose for monitoring primary
chemotherapy in breast cancer. J Clin Oncol 18: 1689–1695
Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S,
Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF (2000)
Positron emission tomography using [
18F]-ﬂuorodeoxy-D-glucose to
predict the pathologic response of breast cancer to primary chemotherapy.
J Clin Oncol 18: 1676–1688
Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission
tomography evaluation of residual radiographic abnormalities in postche-
motherapy germ cell tumor patients. J Clin Oncol 14: 1637–1641
Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a
major problem in the diagnostics of oncological patients. Eur J Nucl
Med 23: 1409–1415
Strauss LG, Conti PS (1991) The applications of PET in clinical oncology. J
Nucl Med 32: 623–648
Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993)
Metabolic monitoring of breast cancer chemohormonotherapy using posi-
tron emission tomography: initial evaluation. J Clin Oncol 11: 2101–2111
Zon RT, Nichols C, Einhorn LH (1998) Management strategies and outcomes
of germ cell tumor patients with very high human chorionic gonadotropin
levels. J Clin Oncol 16: 1294–1297
C
l
i
n
i
c
a
l
PET for prediction of response to HD-CTX in germ cell cancer
C Bokemeyer et al
511
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 506–511